Patricia LEMARCHAND

PU-PH de biologie cellulaire

Contact details

SFR Santé F. Bonamy - UMS inserm 016/ CNRS 3556/FED4203 l'institut du thorax - Inserm UMR1087/CNRS UMR6291 IRS-UN, 8 quai Moncousu, BP 70721, 44007 Nantes cedex 1, France

Fax
02 28 08 01 30
Email
Patricia.Lemarchand@univ-nantes.fr

Taught academic discipline(s)

Cell biology

Research topics

gene and cell therapy, cellular models of cardiovascular disease using iPSCs.

Activities / Resume

Profile Google scholar 

Patricia Lemarchand has long been recognized and awarded for her work on respiratory and cardiovascular gene and cell therapy. She pioneered cardiovascular (Lemarchand et al, PNAS 1992; Circulation Research 1993) and respiratory (Danel et al, Human gene Therapy 1998) gene therapy. She developed several approaches using adenovirus vectors (Foretz et al, Mol Cell Biol 1999; Tralhao et al, FASEB 2003).

Her research is currently based on translational research, from human stem-cell biology (MESSAGE study, NCT00836732) to cell therapy clinical trials (BONAMI clinical trial, NCT00200707, Roncalli et al, Eur Heart J 2011), including rodent and large animal models of gene and cell therapy (Ferrnandes et al, Cardiovasc Res 2006; Brazza et al, Stem Cells 2016).

Stimulated by the development of iPSC technologies, she has recently developed projects including iPSCs, considering their strong potential to develop new strategies in cell therapy and relevant models for cardiovascular diseases (Jouni et al, J Am Heart Assoc 2015; Si-Tayeb K et al, Disease Models & Mechanisms 2016). Together with Laurent David (scientific director), she coordinates the new iPSC core facility of Nantes, that prepares iPSCs for academic and industrial research projects. The iPSC core facility mainly focuses on human iPSCs from healthy individuals and patients with complex genetic diseases, to use these iPSCs to establish physiopathology models, and on rodent iPSCs dedicated to regenerative medicine and pre-clinical trials.

Body

PUPH

Additional informations

Main recent publications:

Dirou S, Chambellan A, Chevallier P, Germaud P, Lamirault G, Gourraud PA, Perrot B, Delasalle B, Forestier B, Guillaume T, Peterlin P, Garnier A, Magnan A, Blanc FX, Lemarchand P. Deconditioning, fatigue and impaired quality of life in long-term survivors after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 2017 (in press).

Lamirault G, de Bock E,Sébille S, Delasalle B, Roncalli J, Susen S, Piot C, Trochu JN, Teiger E, Neuder Y, Le Tourneau T, Manrique A, Hardouin J-B, Lemarchand P. Sustained quality of life improvement after intracoronary injection of autologous bonemarrow cells in the setting of acute myocardial infarction: results from the BONAMI trial. Quality of Life Research 2017; 26:121-125.

Braza F, Dirou S, Forest V, SauzeauV, Hassoun D, Chesné J, Cheminant-Muller M-A, Sagan C, Magnan A, Lemarchand P. Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma. Stem Cells 2016; 209:258-265.

Es-Salah-Lamoureux Z, Jouni M,Malak OA, Belbachir N, Reda Al Sayed Z, Gandon-Renard M, Lamirault G, GauthierC, Baró I, Charpentier F, Zibara K, Lemarchand P, Beaumelle B, Gaborit N, Loussouarn G. HIV-Tat induces a decrease in IKr and IKs via reduction in phosphatidylinositol-(4,5)-bisphosphate availability. Journal of Molecular and Cellular Cardiology 2016; 99:1-13.

Si-Tayeb K, Idriss S, Champon B, Caillaud A, Pichelin M, Arnaud L, Lemarchand P, Le May C, Zibara K, Cariou B. Urine sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis Mod & Mechanisms  2016;9(1):81-90.

Guijarro D, Lebrin M, LairezO, Bourin P, Piriou N, Pozzo J, Landes G, Berry M, Letourneau T, Cussac D, Sensebe L, Gross F, Lamirault G, Huynh A, Manrique A, Ruidavet JB, Elbaz M, Trochu JN, Parini A, Kramer S, Galinier M, Lemarchand P, Roncalli J. Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of theMESAMI 1 pilot trial. International Journal of Cardiology 2016; 209:258-265.

Jouni M, Si-Tayeb K, Es-Salah-Lamoureux Z, Latypova X, Champon B, Caillaud A, Rungoat A, Charpentier F, Loussouarn G, Baró I, Zibara K, Lemarchand P, Gaborit N. Towards Personalized Medicine: Using cardiomyocytes differentiated from urine-derived pluripotent stem cells to recapitulate electrophysiological characteristics of LQT2 syndrome. J Am Heart Assoc 2015;4:e002159.

Gyongyosi M, Wojakowski W, Lemarchand P, et al. Meta-Analysis of Cell-basedCaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 2015 16(8):1346-60. Best manuscript award 2015

Delewi R, Hirsch A, Tijssen JG, Schachinger V, Wojakowski W, Roncalli R, Aakhus S, Erbs S, Assmus B, Tendera M, Lemarchand P, et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative meta-analysis. Eur Heart J 2014; 5(15):989-998.

Lamirault G, Susen S, Forest V, Hemont C, Parini A, Le Corvoisier P, Piot C, Richard MJ, Delasalle B, Rouard H, Sportouch C, Persoons V, Van Belle E, Roncalli J, Lemarchand P. Differential mobilization of progenitor cells in smoker and non-smoker patients with acute myocardial infarction: insights from the BONAMI biology sub-study. Stem Cell Res & Ther 2013; 4:152.

Roncalli J, Mouquet F, Piot C, Trochu JN, Le Corvoisier P, Neuder Y, Le Tourneau T, Agostini D, Gaxotte V, Sportouch C, Galinier M, Crochet D, Teiger E, Richard MJ, Polge AS, Beregi JP, Manrique A, Carrie D, Susen S, Klein B, Parini A, Lamirault G, Croisille P, Rouard H, Bourin P, Nguyen JM, Delasalle B, Vanzetto G, Van Belle E, Lemarchand P. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction:  results of the randomized multicenter BONAMI Trial. Eur Heart J 2011; 32(14): 1748-1757.